1. MSI

3. Content Outline

4. Microsatellite Instability in Cancer

5. Prognostic Impact of Microsatellite Instability in CRC

6. KEYNOTE-016 Emergence of MSI Status as a Predictive Biomarker

7. Methods to Test for Microsatellite Instability

8. Patient Case Colorectal Cancer

9. Optimal Treatment Selection for mCRC Depends on Molecular Testing

10. Evolving Society Guidelines on Molecular Testing

11. KEYNOTE-164 Data

12. Contrasting Pembrolizumab With Standard Later-Line Therapies

13. KEYNOTE-028 Can PD-L1 Predict Responses to PD-1 Therapy?

14. CheckMate-142 What Is the Optimal Immunotherapy Approach for MSI-H CRC?

15. CheckMate 142 Single-Agent Nivolumab in MSI-H CRC

16. CheckMate-142 Nivolumab-Ipilimumab Combination Results

17. Single-Agent or Combination Immunotherapy?

18. Does It Matter Whether MSI-H Status Is Germline or Somatic?

19. First-Line Immunotherapy for CRC on the Horizon

20. Patient Case #2 Gastric Cancer

21. Gastric Cancer Differs From Colorectal Cancer in Terms of Immunotherapy Response

22. KEYNOTE-059 Cohort 1 A Role for PD-1 Inhibition in Previously Treated Gastric Cancer

23. KEYNOTE-061 Pembrolizumab in Gastric/GEJ Cancer — Randomized Trial

24. KEYNOTE-062 Adding Pembrolizumab to Chemotherapy for Previously Treated Gastric/GEJ Cancer

25. PD-L1 May Not Be a Binary Biomarker

26. CheckMate-032 Combination Immunotherapy for Advanced Gastric Cancer

27. MSI Status as a Universal Biomarker Across Solid Tumors

28. Key Takeaways

29. Abbreviations

30. Abbreviations (cont)

31. Abbreviations (cont)